[Pattern of Recurrence and Metastasis After Radical Resection of  Non-small Cell Lung Cancer]

Overview

Journal Zhongguo Fei Ai Za Zhi

Specialties Oncology
Pulmonary Medicine

Date 2022 Jan 25

PMID 35078282

Authors

Xianping Liu

Xiao Li

Fan Yang

Affiliations

Soon will be listed here.

Abstract

The rate of recurrence and metastasis of non-small cell lung cancer after radical resection is still very high. The risk factors for recurrence and metastasis have been extensively studied, but the dynamic pattern of postoperative recurrence hazard over time is relatively lacking. The dynamic recurrence hazard rate curve is applied to describe the rate of recurrence at any point time among the "at-risk" patients. In this article, by reviewing the previous literature, the characteristics of the dynamic recurrence and metastasis pattern after radical resection of non-small cell lung cancer and the clinical factors affecting the recurrence and metastasis pattern are summarized, in order to screen out specific populations with high recurrence risk and give them personalized follow-up strategy and diagnosis and treatment. .

Citing Articles

[Predictive Value of A miRNA Signature for Distant Metastasis in Lung Cancer].

Cong J, Wang A, Wang Y, Li X, Pi J, Liu K Zhongguo Fei Ai Za Zhi. 2025; 27(12):919-930.

PMID: 39962847 PMC: 11839496. DOI: 10.3779/j.issn.1009-3419.2024.102.43.

Long-term survival and failure patterns in inoperable early-stage non-small cell lung cancer following stereotactic body radiotherapy: a single-institution retrospective study.

Wang L, Wang R, Wei Z, Wang Y, Chen H, Dong B Sci Rep. 2024; 14(1):30076.

PMID: 39627240 PMC: 11614887. DOI: 10.1038/s41598-024-73177-2.

Comparative proteomic analysis between tumor tissues and intratumoral exosomes from lung adenocarcinoma patients identifies PAFAH1B3 as an exosomal protein key for initiating metastasis in lung adenocarcinoma.

Wang C, Xiao L, Gao L, Wu J, Wang S, Zheng M Heliyon. 2024; 10(21):e39859.

PMID: 39553628 PMC: 11567031. DOI: 10.1016/j.heliyon.2024.e39859.

References

Brandt W, Bouabdallah I, Tan K, Park B, Adusumilli P, Molena D . Factors associated with distant recurrence following R0 lobectomy for pN0 lung adenocarcinoma. J Thorac Cardiovasc Surg. 2017; 155(3):1212-1224.e3. PMC: 5816702. DOI: 10.1016/j.jtcvs.2017.09.151. View

Wong M, McMurry T, Stukenborg G, Francescatti A, Amato-Martz C, Schumacher J . Impact of age and comorbidity on treatment of non-small cell lung cancer recurrence following complete resection: A nationally representative cohort study. Lung Cancer. 2016; 102:108-117. PMC: 5172386. DOI: 10.1016/j.lungcan.2016.11.002. View

Hashimoto M, Tanaka F, Yoneda K, Takuwa T, Matsumoto S, Okumura Y . Significant increase in circulating tumour cells in pulmonary venous blood during surgical manipulation in patients with primary lung cancer. Interact Cardiovasc Thorac Surg. 2014; 18(6):775-83. DOI: 10.1093/icvts/ivu048. View

Kim J, Bae J . Tumor-Associated Macrophages and Neutrophils in Tumor Microenvironment. Mediators Inflamm. 2016; 2016:6058147. PMC: 4757693. DOI: 10.1155/2016/6058147. View

Pantel K, Brakenhoff R, Brandt B . Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer. 2008; 8(5):329-40. DOI: 10.1038/nrc2375. View

Patel S, Rimner A, Foster A, Zhang Z, Woo K, Yu H . Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib. Lung Cancer. 2017; 108:109-114. PMC: 5477661. DOI: 10.1016/j.lungcan.2017.03.010. View

Hung J, Jeng W, Hsu W, Chou T, Huang B, Wu Y . Predictors of death, local recurrence, and distant metastasis in completely resected pathological stage-I non-small-cell lung cancer. J Thorac Oncol. 2012; 7(7):1115-23. DOI: 10.1097/JTO.0b013e31824cbad8. View

Chen Y, Song Y, Du W, Gong L, Chang H, Zou Z . Tumor-associated macrophages: an accomplice in solid tumor progression. J Biomed Sci. 2019; 26(1):78. PMC: 6800990. DOI: 10.1186/s12929-019-0568-z. View

Han J, Park K, Kim S, Lee D, Kim H, Kim H . First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol. 2012; 30(10):1122-8. DOI: 10.1200/JCO.2011.36.8456. View

10.

Hattori A, Matsunaga T, Takamochi K, Oh S, Suzuki K . Prognostic impact of a ground glass opacity component in the clinical T classification of non-small cell lung cancer. J Thorac Cardiovasc Surg. 2017; 154(6):2102-2110.e1. DOI: 10.1016/j.jtcvs.2017.08.037. View

11.

Lou F, Huang J, Sima C, Dycoco J, Rusch V, Bach P . Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillance. J Thorac Cardiovasc Surg. 2012; 145(1):75-81. DOI: 10.1016/j.jtcvs.2012.09.030. View

12.

Morales-Oyarvide V, Mino-Kenudson M . High-grade lung adenocarcinomas with micropapillary and/or solid patterns: a review. Curr Opin Pulm Med. 2014; 20(4):317-23. DOI: 10.1097/MCP.0000000000000070. View

13.

Tanaka F, Yoneda K, Kondo N, Hashimoto M, Takuwa T, Matsumoto S . Circulating tumor cell as a diagnostic marker in primary lung cancer. Clin Cancer Res. 2009; 15(22):6980-6. DOI: 10.1158/1078-0432.CCR-09-1095. View

14.

Hung J, Yeh Y, Wu Y, Chou T, Hsu W . Prognostic Factors in Completely Resected Node-Negative Lung Adenocarcinoma of 3 cm or Smaller. J Thorac Oncol. 2017; 12(12):1824-1833. DOI: 10.1016/j.jtho.2017.07.009. View

15.

Inoue M, Minami M, Sawabata N, Utsumi T, Kadota Y, Shigemura N . Clinical outcome of resected solid-type small-sized c-stage IA non-small cell lung cancer. Eur J Cardiothorac Surg. 2010; 37(6):1445-9. DOI: 10.1016/j.ejcts.2009.12.030. View

16.

Heon S, Yeap B, Lindeman N, Joshi V, Butaney M, Britt G . The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clin Cancer Res. 2012; 18(16):4406-14. PMC: 3682221. DOI: 10.1158/1078-0432.CCR-12-0357. View

17.

Li M, He H, Ruan Z, Zhu Y, Li R, He X . Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study. BMC Cancer. 2017; 17(1):245. PMC: 5379522. DOI: 10.1186/s12885-017-3165-0. View

18.

Hanin L . Seeing the invisible: how mathematical models uncover tumor dormancy, reconstruct the natural history of cancer, and assess the effects of treatment. Adv Exp Med Biol. 2012; 734:261-82. DOI: 10.1007/978-1-4614-1445-2_12. View

19.

Ettinger D, Wood D, Aisner D, Akerley W, Bauman J, Bharat A . NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. J Natl Compr Canc Netw. 2021; 19(3):254-266. DOI: 10.6004/jnccn.2021.0013. View

20.

Deng C, Zhang Y, Ma Z, Fu F, Deng L, Li Y . Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma. J Thorac Cardiovasc Surg. 2020; 162(3):664-674.e7. DOI: 10.1016/j.jtcvs.2020.05.099. View

[Pattern of Recurrence and Metastasis After Radical Resection of Non-small Cell Lung Cancer]

[Pattern of Recurrence and Metastasis After Radical Resection of  Non-small Cell Lung Cancer]